We’re proud of our legacy as a leader in the treatment of B-cell malignancies, and we’re excited about the potential of cell therapy beyond blood cancers. By broadening our scientific discovery efforts across new technologies and disease areas, we’re pursuing our goal of achieving cures – for cancer and potentially other diseases – with cell therapy.
Kite is continuing to further our leadership in blood cancers, such as large B-cell lymphoma (LBCL), follicular lymphoma (FL) and multiple myeloma (investigational). Despite advances in LBCL, there is still a need to improve upon current treatment options across cure rate, toxicity and accessibility. Kite is exploring next-generation CAR Ts with dual antigen targeting to potentially improve upon the available treatment options for LBCL patients.
Unlike hematological malignancies, applying CAR T-cell therapy to the treatment of solid tumors has posed challenges historically. We’re currently exploring how cell therapy can potentially be leveraged for the treatment of solid tumors such as hepatocellular cancer (HCC), glioblastoma and neuroblastoma.
The potential application of cell therapy to autoimmune diseases is an exciting area of focus for Kite. We’re taking our learnings from hematological malignancies and examining how cell therapy can potentially be used to treat autoimmune diseases like systemic lupus erythematosus, lupus nephritis, scleroderma and myositis.